Literature DB >> 23606425

Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging.

Zhen Ye1, Xueming Wu, Mingqian Tan, Jack Jesberger, Mark Grisworld, Zheng-Rong Lu.   

Abstract

Macromolecular Gd(III)-based contrast agents are effective for contrast-enhanced blood pool and cancer MRI in preclinical studies. However, their clinical applications are impeded by potential safety concerns associated with slow excretion and prolonged retention of these agents in the body. To minimize the safety concerns of macromolecular Gd contrast agents, we have developed biodegradable macromolecular Gd contrast agents based on polydisulfide Gd(III) complexes. In this study, we designed and synthesized a new generation of the polydisulfide Gd(III) complexes containing a macrocyclic Gd(III) chelate, Gd-DOTA monoamide, to improve the in vivo kinetic inertness of the Gd(III) chelates. (N6-Lysyl)lysine-(Gd-DOTA) monoamide and 3-(2-carboxyethyldisulfanyl)propanoic acid copolymers (GODC) were synthesized by copolymerization of (N6-lysyl)lysine DOTA monoamide and dithiobis(succinimidylpropionate), followed by complexation with Gd(OAc)3. The GODC had an apparent molecular weight of 26.4 kDa and T1 relaxivity of 8.25 mM(-1) s(-1) per Gd at 1.5 T. The polymer chains of GODC were readily cleaved by L-cysteine and the chelates had high kinetic stability against transmetallation in the presence of an endogenous metal ion Zn(2+). In vivo MRI study showed that GODC produced strong and prolonged contrast enhancement in the vasculature and tumor periphery of mice with breast tumor xenografts. GODC is a promising biodegradable macromolecular MRI contrast agent with high kinetic stability for MR blood pool imaging.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23606425      PMCID: PMC4060968          DOI: 10.1002/cmmi.1520

Source DB:  PubMed          Journal:  Contrast Media Mol Imaging        ISSN: 1555-4309            Impact factor:   3.161


  48 in total

1.  MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.

Authors:  K Turetschek; E Floyd; T Helbich; T P Roberts; D M Shames; M F Wendland; W O Carter; R C Brasch
Journal:  J Magn Reson Imaging       Date:  2001-09       Impact factor: 4.813

2.  Rationale and applications for macromolecular Gd-based contrast agents.

Authors:  R C Brasch
Journal:  Magn Reson Med       Date:  1991-12       Impact factor: 4.668

3.  Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice.

Authors:  Yuda Zong; Xinghe Wang; K Craig Goodrich; Aaron M Mohs; Dennis L Parker; Zheng-Rong Lu
Journal:  Magn Reson Med       Date:  2005-04       Impact factor: 4.668

Review 4.  MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report.

Authors:  R Brasch; K Turetschek
Journal:  Eur J Radiol       Date:  2000-06       Impact factor: 3.528

5.  Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents.

Authors:  Zheng-Rong Lu; Xueming Wu
Journal:  Isr J Chem       Date:  2010-08       Impact factor: 3.333

6.  A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics.

Authors:  T H Helbich; A Gossman; P A Mareski; B Radüchel; T P Roberts; D M Shames; M Mühler; K Turetschek; R C Brasch
Journal:  J Magn Reson Imaging       Date:  2000-06       Impact factor: 4.813

7.  Poly(l-glutamic acid) Gd(III)-DOTA conjugate with a degradable spacer for magnetic resonance imaging.

Authors:  Zheng-Rong Lu; Xinghe Wang; Dennis L Parker; K Craig Goodrich; Henry R Buswell
Journal:  Bioconjug Chem       Date:  2003 Jul-Aug       Impact factor: 4.774

Review 8.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

9.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

Review 10.  Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Authors:  Anwar R Padhani
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

View more
  10 in total

1.  Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Authors:  Clemens C Cyran; Yanjun Fu; Victor Rogut; Bundit Chaopathomkul; Michael F Wendland; David M Shames; Robert C Brasch
Journal:  Acad Radiol       Date:  2013-10       Impact factor: 3.173

2.  Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer.

Authors:  Kannika Khantasup; Pairash Saiviroonporn; Suwatchai Jarussophon; Warangkana Chantima; Tararaj Dharakul
Journal:  MAGMA       Date:  2018-05-08       Impact factor: 2.310

3.  Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.

Authors:  Anthony S Malamas; Erlei Jin; Qi Zhang; John Haaga; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2015-04-04       Impact factor: 4.200

4.  Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

Authors:  Xueming Wu; Guanping Yu; Daniel Lindner; Susann M Brady-Kalnay; Qi Zhang; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-07-15

5.  Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.

Authors:  Xueming Wu; Niranjan Balu; Wen Li; Yong Chen; Xiaoyue Shi; China M Kummitha; Xin Yu; Chun Yuan; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

6.  A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.

Authors:  Zhen Ye; Zhuxian Zhou; Nadia Ayat; Xueming Wu; Erlei Jin; Xiaoyue Shi; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2015-07-27       Impact factor: 3.161

7.  Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.

Authors:  Zhuxian Zhou; Xueming Wu; Adam Kresak; Mark Griswold; Zheng-Rong Lu
Journal:  Biomaterials       Date:  2013-07-14       Impact factor: 12.479

8.  Fluorescent single-stranded DNA-based assay for detecting unchelated Gadolinium(III) ions in aqueous solution.

Authors:  Osafanmwen Edogun; Nghia Huu Nguyen; Marlin Halim
Journal:  Anal Bioanal Chem       Date:  2016-04-12       Impact factor: 4.142

9.  High dynamic range processing for magnetic resonance imaging.

Authors:  Andy H Hung; Taiyang Liang; Preeti A Sukerkar; Thomas J Meade
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

10.  Redox-triggered self-assembly of gadolinium-based MRI probes for sensing reducing environment.

Authors:  Deju Ye; Prachi Pandit; Paul Kempen; Jianguo Lin; Liqin Xiong; Robert Sinclair; Brian Rutt; Jianghong Rao
Journal:  Bioconjug Chem       Date:  2014-07-21       Impact factor: 4.774

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.